Stockscreener 앱 받기
24.46
5.49%
-1.42
시간 외 거래:
24.46
전일 마감가:
$25.88
열려 있는:
$26.07
하루 거래량:
720.50K
Relative Volume:
1.03
시가총액:
$1.05B
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
16.87
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
-7.73%
1개월 성능:
+1.62%
6개월 성능:
+5.39%
1년 성능:
+33.44%
1일 변동 폭
$24.20
$26.81
1주일 범위
$24.20
$26.81
52주 변동 폭
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.46 | 1.11B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
125.90 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
(PCRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Big and small, Bay Area companies catch eye of activist shareholders at year's end - The Business Journals
Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale - marketscreener.com
DOMA to nominate three directors to Pacira board, urges company sale By Investing.com - Investing.com Nigeria
DOMA Perpetual Pushes for Strategic Changes at Pacira BioSciences (PCRX) - GuruFocus
Pacira (PCRX) Faces Push for Leadership Change and Strategic Rev - GuruFocus
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - Seeking Alpha
Doma Perpetual Capital Management asserts Pacira BioSciences's board to pursue sale of company - marketscreener.com
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. - PR Newswire
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc. - MarketBeat
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC - MarketBeat
Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Neelam Linens and Garments (India) Limited Benefit From Sector TailwindsConsumer Goods Stocks & Free Stock Index Interpretations - bollywoodhelpline.com
OA Gets a Data-Driven PROBE Makeover - Orthopedics This Week
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Investors May Respond To Pacira BioSciences (PCRX) Joining AI-Driven PROBE Osteoarthritis Consortium - Sahm
Pacira BioSciences (PCRX) price target decreased by 18.47% to 30.77 - MSN
Price-Driven Insight from (PCRX) for Rule-Based Strategy - news.stocktradersdaily.com
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock maintain momentum in 2025Stop Loss & Weekly Breakout Opportunity Watchlist - Улправда
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care - Ortho Spine News
Will Pacira BioSciences Inc. (82P) stock deliver stable dividendsJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
How geopolitical tensions affect Pacira BioSciences Inc. stockWeekly Profit Report & Safe Capital Preservation Plans - DonanımHaber
Why Pacira BioSciences Inc. stock remains a top recommendationJuly 2025 PreEarnings & Short-Term High Return Strategies - DonanımHaber
How rising interest rates impact Pacira BioSciences Inc. stockQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Pacira BioSciences (PCRX): Assessing Valuation After New PROBE Consortium Osteoarthritis AI Initiative - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock nowJuly 2025 Highlights & Free Reliable Trade Execution Plans - Улправда
Pacira (PCRX) Joins Global Effort to Enhance Osteoarthritis Rese - GuruFocus
Pacira BioSciences (PCRX): Reassessing Valuation After a 45% Year‑to‑Date Share Price Rally - Yahoo Finance
Pacira BioSciences stock earns technical rating upgrade - MSN
Pacira BioSciences (PCRX) Is Up 7.7% After Positive Spine Pain Pilot Data and New FDA ClearanceHas The Bull Case Changed? - Sahm
Pacira BioSciences Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares - MarketBeat
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock - MarketBeat
Pacira Biosciences CFO cross sells $626k in shares By Investing.com - Investing.com India
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Pacira BioSciences CFO Shawn Cross Sells 25,000 Shares - TradingView — Track All Markets
CFO Cross Sells 25,000 ($626.8K) Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
Natixis Buys 151,250 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
(PCRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
CFO Cross Files To Sell 9,104 Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pacira Biosciences Inc 주식 (PCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cross Shawn | Chief Financial Officer |
Dec 10 '25 |
Option Exercise |
16.45 |
9,104 |
149,761 |
65,354 |
| Cross Shawn | Chief Financial Officer |
Dec 09 '25 |
Sale |
25.03 |
15,896 |
397,877 |
56,250 |
| Cross Shawn | Chief Financial Officer |
Dec 10 '25 |
Sale |
25.14 |
9,104 |
228,875 |
56,250 |
2.19%
0.08%
자본화:
|
볼륨(24시간):